Madecassoside alleviates Clostridioides difficile infection by targeting ASC to inhibit inflammasome activation
Authors:
- 29 August 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 165, 115440
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82372306, 82172324)
This publication has 50 references indexed in Scilit:
- Asiaticoside exerts neuroprotection through targeting NLRP3 inflammasome activationPhytomedicine, 2024
- A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseasesCell, 2023
- TFPI is a colonic crypt receptor for TcdB from hypervirulent clade 2 C. difficileCell, 2022
- European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adultsClinical Microbiology and Infection, 2021
- In-vitro study of the effect of Centella asiatica on cholera toxin production and the gene expression level of ctxA gene in Vibrio cholerae isolatesJournal of Ethnopharmacology, 2021
- Clostridium difficile and One HealthClinical Microbiology and Infection, 2020
- Asiaticoside loading into polylactic‐co‐glycolic acid electrospun nanofibers attenuates host inflammatory response and promotes M2 macrophage polarizationJournal of Biomedical Materials Research Part A, 2019
- Inflammasome Complexes: Emerging Mechanisms and Effector FunctionsCell, 2016
- Intestinal Inflammatory Biomarkers and Outcome in Pediatric Clostridium difficile InfectionsThe Journal of Pediatrics, 2013
- Toxin A-negative, toxin B-positive Clostridium difficileInternational Journal of Infectious Diseases, 2007